AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$RVMD

Sandler Alan B. sold $1.3M of RVMD

Sandler Alan B. (Chief Development Officer) sold 6,309 shares of Revolution Medicines, Inc. (RVMD) at an average of $202.14 ($200.82–$204.72, $1.28M total) across 5 trades on 2026-09-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sandler Alan B.
Published Oct 1, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RVMD
Bearish
high confidence
Mentioned
$RVMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDBearishLow
01

Why it matters

The insider sale is a material event for RVMD, likely generating short‑term pressure but not altering long‑term fundamentals.

02

Market read

First‑report insider sale of $1.3 M, modest impact on RVMD price.

03

What to watch

Potential upcoming clinical data releases could offset any negative sentiment from the insider sale.

Relevance 5/10Novelty 7/10Timing: after‑hours on 2026‑09‑29

Background

Form 4 filings are primary disclosures; this sale is the first public report of the transaction.

Company-level read

Ticker impact

$RVMDBearishHigh confidence
Context

Chief Development Officer Sandler Alan B. sold $1.3M of RVMD shares via a 10b5‑1 plan, reducing his stake to 52,559 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

A C-level insider sold over 6,300 shares at $200‑$205 each, a material amount for a mid‑cap biotech, and such sales often trigger short‑term sell‑offs.

Market effects

Sector

May prompt modest re‑rating of biotech insider activity risk.

Regional

Limited to U.S. biotech investors.

Global

Low; impact confined to RVMD shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

  • company
    Revolution Medicines, Inc.

    Biotech firm developing oncology therapies, ticker RVMD.

  • person
    Alan B. Sandler

    Chief Development Officer of Revolution Medicines.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVMD insider trading history →

Related articles

OCT 19
$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

european-biotechnology.com3 min
OCT 16
$RVMDMed

October 2026 EMA/CHMP recommendations

The European Medicines Agency's CHMP recommended six medicines, including Revolution Medicines' Rasonque, for approval. Rasonque targets metastatic pancreatic cancer and was prioritized under EMA's Cancer Medicines Pathfinder project.

thepharmaletter.com2 min
OCT 16
$RVMDHigh

Guggenheim reiterates Buy on Revolution stock after EU regulatory opinion

Guggenheim maintained a Buy rating and $275 price target on Revolution Medicines (NASDAQ:RVMD) after the European Medicines Agency recommended approval of its drug Rasonque. The stock has risen 281% in the past year, though some analysts suggest it may be overvalued. Multiple firms have recently initiated coverage with positive ratings and price targets ranging from $226 to $318.

investing.com2 min
OCT 16
$LLYHigh

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

tradingview.com2 min
OCT 16
$RVMDHigh

William Blair initiates Revolution stock with outperform on RAS franchise

William Blair initiated coverage on Revolution Medicines (RVMD) with an Outperform rating and a $226 price target. The stock has gained 281% over the past year. The FDA approved Rasonque (daraxonrasib) for pancreatic cancer, with trials showing improved survival rates. Analysts cite strong early launch trends and commercial potential, though some note overvaluation. Multiple firms raised price targets following the approval.

investing.com1 min
OCT 15
$RVMDMed

Revolution Medicines receives EU committee backing for pancreatic cancer drug

Revolution Medicines (RVMD) announced the EMA's Committee for Medicinal Products for Human Use issued a positive opinion for RASONQUE as a monotherapy for adult patients with metastatic pancreatic adenocarcinoma. The recommendation is based on Phase 3 trial results showing RASONQUE improved overall survival (13.2 months vs. 6.7 months with chemotherapy) and progression-free survival (7.2 months vs. 3.6 months). The EMA's expedited review process was used.

investing.com5 min